Literature DB >> 21880354

Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: a prospective study.

Alfredo J Lucendo1, Angel Arias, Livia C De Rezende, Jose Luis Yagüe-Compadre, Teresa Mota-Huertas, Sonia González-Castillo, Rubén A Cuesta, José M Tenias, Teresa Bellón.   

Abstract

BACKGROUND: Recent research shows that both pediatric and adult patients with eosinophilic esophagitis (EoE) experience esophageal remodeling marked by increased collagen deposition in which TGF-β plays an important role. However, limited data are available on the intensity and reversibility of fibrous remodeling in adults with EoE.
OBJECTIVE: We sought to analyze differences in collagen deposition in the lamina propria (LP) and profibrogenic cytokine gene expression along with other changes induced by prolonged treatment with fluticasone propionate in adults with EoE.
METHODS: Ten adults given consecutive diagnoses of EoE were studied prospectively. Deep esophageal biopsy specimens were obtained before and after 1 year of treatment with fluticasone propionate. Collagen deposition in the LP was assessed in tissue sections with the aid of the Masson trichrome technique. IL5, TGFB1, fibroblast growth factor 9 (FGF9), and CCL18 gene expression was quantified through real-time PCR. EoE results were compared among samples from 10 adult patients with gastroesophageal reflux disease and 10 control subjects with healthy esophagi.
RESULTS: Patients with EoE showed a significant increase in subepithelial collagen deposition; this correlated positively with eosinophil density in the LP and the patient's age. Prolonged steroid treatment induced a nonsignificant reduction in subepithelial fibrosis, which remained significantly higher than in control subjects. Profibrogenic cytokine gene expression also increased in patients with EoE, with IL5 (P < .001), FGF9 (P = .005), and CCL18 (P = .008) all significantly upregulated. After 1 year of treatment, a reduction was observed in gene expression; for CCL18 expression, this decrease was statistically significant (P < .001).
CONCLUSIONS: Esophageal remodeling is associated with upregulated gene expression of profibrogenic cytokines in adults with EoE. Prolonged treatment with fluticasone propionate leads to a nonsignificant reduction in subepithelial collagen deposition accompanied by downregulation of profibrogenic cytokine gene expression, with that of CCL18 being especially significant. Copyright Â
© 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880354     DOI: 10.1016/j.jaci.2011.08.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  68 in total

1.  Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment.

Authors:  Amir F Kagalwalla; Noorain Akhtar; Samantha A Woodruff; Bryan A Rea; Joanne C Masterson; Vincent Mukkada; Kalyan R Parashette; Jian Du; Sophie Fillon; Cheryl A Protheroe; James J Lee; Katie Amsden; Hector Melin-Aldana; Kelley E Capocelli; Glenn T Furuta; Steven J Ackerman
Journal:  J Allergy Clin Immunol       Date:  2012-04-01       Impact factor: 10.793

Review 2.  Management of proton pump inhibitor responsive-esophageal eosinophilia and eosinophilic esophagitis: controversies in treatment approaches.

Authors:  Bharati Kochar; Evan S Dellon
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-12       Impact factor: 3.869

3.  Eosinophilic Esophagitis-Associated Chemical and Mechanical Microenvironment Shapes Esophageal Fibroblast Behavior.

Authors:  Amanda B Muir; Kara Dods; Steven J Henry; Alain J Benitez; Dale Lee; Kelly A Whelan; Maureen DeMarshall; Daniel A Hammer; Gary Falk; Rebecca G Wells; Jonathan Spergel; Hiroshi Nakagawa; Mei-Lun Wang
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-08       Impact factor: 2.839

4.  A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease.

Authors:  Evan S Dellon; Hannah P Kim; Sarah L W Sperry; David A Rybnicek; John T Woosley; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2013-11-23       Impact factor: 9.427

Review 5.  Recent advances in the recognition and management of eosinophilic esophagitis.

Authors:  Gregory Eustace; Xianyong Gui; Marietta Iacucci
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

6.  The esophageal biopsy "pull" sign: a highly specific and treatment-responsive endoscopic finding in eosinophilic esophagitis (with video).

Authors:  Evan S Dellon; Jessica H Gebhart; Leana L Higgins; Kelly E Hathorn; John T Woosley; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2015-07-02       Impact factor: 9.427

Review 7.  White Paper AGA: Drug Development for Eosinophilic Esophagitis.

Authors:  Ikuo Hirano; Stuart Spechler; Glenn Furuta; Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-22       Impact factor: 11.382

8.  Outcomes of Esophageal Dilation in Eosinophilic Esophagitis: Safety, Efficacy, and Persistence of the Fibrostenotic Phenotype.

Authors:  Thomas M Runge; Swathi Eluri; Cary C Cotton; Caitlin M Burk; John T Woosley; Nicholas J Shaheen; Evan S Dellon
Journal:  Am J Gastroenterol       Date:  2016-01-12       Impact factor: 10.864

Review 9.  Eosinophilic esophagitis.

Authors:  Jamie Merves; Amanda Muir; Prasanna Modayur Chandramouleeswaran; Antonella Cianferoni; Mei-Lun Wang; Jonathan M Spergel
Journal:  Ann Allergy Asthma Immunol       Date:  2014-02-22       Impact factor: 6.347

10.  From genetics to treatment of eosinophilic esophagitis.

Authors:  Antonella Cianferoni; Jonathan M Spergel
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.